Feb 26 (Reuters) - Emergent Biosolutions Inc:
* EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS
* EMERGENT BIOSOLUTIONS INC - INITIAL DATA FROM PHASE 1 CLINICAL TRIAL OF VLA1601 ARE EXPECTED TO BE AVAILABLE IN LATE 2018 OR EARLY 2019 Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.